RecruitingNot ApplicableNCT07014111
Fight Fatigue: A Progressive Muscle Relaxation and Walking Intervention to Reduce Fatigue in Adults With ESKD
Sponsor
University of Illinois at Chicago
Enrollment
40 participants
Start Date
Sep 2, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Fight Fatigue is evaluating the feasibility and acceptability of a combined progressive muscle relaxation and walking intervention to reduce fatigue for adults with end-stage kidney disease receiving in-center hemodialysis.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Diagnosis of ESKD diagnosis and receiving hemodialysis for at least 3 months
- Can read and speak English
- Fatigue measured via visual analogue scale, score ≥4 over the last week
- Able to stand and walk one block
- Has a cell phone that can receive text messages
Exclusion Criteria6
- Patient's nephrologist refuses for them to participate
- Unstable angina
- Unstable pulmonary disease or pulmonary symptoms that preclude participation
- Lower-extremity amputation without prosthetic (BKA, AKA) -Orthopedic or neurologic condition that would preclude walking or tensing/releasing of muscles-
- Cognitive impairment that, in the judgement of the research team, precludes trial participation
- Participation in the formative phase of the development of Fight Fatigue
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BEHAVIORALFight Fatigue
Combined progressive muscle relaxation and walking (increasing step count) 12-week intervention that consists of education/training followed by text messages.
OTHERAttention Control
End-stage kidney disease education
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07014111
Related Trials
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT0671265431 locations
Comparing Surgical and Endovascular Arteriovenous Fistula Creation
NCT056541032 locations
Coated Aldehyde Oxystarch for Protein-Bound Uremic Toxin Reduction in End-Stage Renal Disease
NCT076537111 location
Changes in Regional Ventilation-Perfusion Match Following Percutaneous Transluminal Angioplasty for Arteriovenous Graft Thrombosis
NCT076136321 location
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
NCT056719911 location